ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.

Biotechnology

Health Care

Test & Measurement

REPROCELL

Chikafumi Yokoyama

Allison Francis

Litong Liu

Karen Bingham

Yasuyuki Asai

Chirag Tawde

Graeme Macluskie

Ejaz Ansari

David Bunton

Rama Modali

Yoshiyuki Yamakawa

Daisuke Usui

The Research and Development team at ReproCELL is dedicated to advancing stem cell technologies by conducting cutting-edge research to innovate and refine regenerative medicine applications. This team focuses on developing high-quality reagents for human ES/iPS cell research and enhancing clinical testing methodologies, ensuring the effective translation of stem cell science into practical healthcare solutions. Their expertise spans various roles, including laboratory management, project direction, and specialized stem cell research, driving the company’s mission to lead in the field of regenerative medicine.

Research and Development

Sales and Marketing

Leadership Team

Research and Development

About

Team members

Other teams at REPROCELL

Sales and Marketing

Leadership Team